Skip to main content
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NameAducanumabCAS Registry Number 1384260-65-4

Physical Data

No data available

Spectra

No data available

Route of Synthesis (ROS)

No data available

Safety and Hazards

No data available

Other Data

No data available

Use PatternAducanumab CAS#: 1384260-65-4 is a human monoclonal antibody and is the first and only Alzheimer's disease treatment to address the clear pathology of the disease by reducing amyloid plaques in the brain. ADUHELM™ is indicated for the treatment of Alzheimer's disease. This indication was granted under accelerated approval for amyloid plaque reduction in patients treated with ADUHELM™.
https://www.chemwhat.com/aducanumab-cas-1384260-65-4/

Comments

Post a Comment

Popular posts from this blog

Overcoming the "Choke Points" in Semaglutide Side Chain Synthesis with Core Technologies to Enable Efficient GLP-1 Drug Manufacturing

Semaglutide, a groundbreaking product in the GLP-1 drug class, owes its extended half-life and enhanced receptor affinity largely to its unique side chain, Ste-Glu-AEEA-AEEA-OSU (CAS: 1169630-40-3) . This side chain covalently modifies the peptide backbone, significantly improving pharmacokinetics and therapeutic performance. However, its complex structure presents two critical synthetic challenges: Precise Assembly of Repetitive AEEA Units: The side chain features consecutive AEEA (aminoethoxyethoxyacetic acid) units, which require stepwise coupling via highly activated intermediates (e.g., AEEA-AEEA). Any impurities or deviations compromise downstream reaction efficiency and may trigger irreversible byproducts. Stereochemistry and Stability of Glutamic Acid (Glu): The glutamic acid component must maintain strict L-configuration, and its carboxyl groups require directional protection (e.g., OtBu) to preserve biological activity. Leveraging deep expertise in peptide chemistry a...
Post a Comment
Read more
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data Identification Product NameBCTA-4NH2IUPAC NameMolecular StructureCAS Registry Number 2559708-42-6Synonyms4,4',4",4"'-(-3,3',6,6'-tetrayl)tetraanilineMolecular FormulaC48H36N6Molecular Weight696.86 Physical Data AppearanceYellow to white powder Spectra No data available BCTA-4NH2 CAS#：2559708-42-6 NMR Route of Synthesis (ROS) No data available Safety and Hazards No data available Other Data TransportationStore at 2-8°C away from light for long time storageStore at 2-8°C away from light for long time storageHS CodeStorageStore at 2-8°C away from light for long time storageShelf Life1 yearMarket Price Toxicity/Safety PharmacologyQuantitative Results Use PatternBCTA-4NH2 CAS#: 2559708-42-6 is an organic compound with a wide range of applications. One of its primary uses is in the field of organic electronics, where it is used as a hole-transport material in organic light-emitti...
Post a Comment
Read more

Watson Chem: Pioneering Advanced Semiconductor Materials for a Sustainable Future

In today’s rapidly advancing technological landscape, the innovation of materials science is driving progress across various high-tech sectors. As a R&D platform of Watson International, Watson Chem has positioned itself at the forefront of semiconductor materials development, becoming a trusted partner for leading global research institutions, energy companies, and high-tech firms. By focusing on extreme purity and stability, Watson Chem specializes in creating cutting-edge semiconductor materials that underpin the breakthrough technologies of tomorrow. Core Competency: Extreme Purity and Stability Watson Chem’s semiconductor materials encompass a range of ultra-pure elements, oxides, sulfides, tellurides, selenides, antimonides, and other semiconductor compounds, available in purity levels ranging from 3N to 7N and beyond. These materials meet the stringent requirements of the most advanced research fields, providing the solid foundation needed for breakthrough innovations. Tru...
Post a Comment
Read more